As part of its mission, the PMC publishes The Case for Personalized Medicine. Since the first edition was published three years ago, the number of prominent examples of personalized medicine treatments and diagnostics has increased from 13 products (69 percent of which were for cancer) to 37 products (56 percent of which were for cancer).

The PMC is now pleased to release the second edition of The Case for Personalized Medicine. This report details how personalized medicine plays an increasingly integral role in delivering high-quality, cost-effective healthcare and presents evidence that personalized medicine will continue to grow in importance as scientific breakthroughs are translated into a new generation of targeted therapeutics. The report also surveys the opportunities and challenges that might affect the pace of adoption, and features comments from industry and government on the potential of personalized medicine and its place in the future of healthcare. This report is underwritten in part by the Ernst & Young Global Biotechnology Center.

Highlights from the report include:

•    An analysis of the current landscape in personalized medicine

•    Real-world demonstrations of how personalized medicine is:
o    Shifting emphasis in medicine from reaction to prevention
o    Enabling the selection of optimal therapy and reducing trial-and-error prescribing
o    Making the use of drugs safer by avoiding adverse drug reactions
o    Increasing patient compliance with treatment
o    Reducing the time and cost of clinical trials
o    Reviving drugs that are failing in clinical trials or were withdrawn from the market
o    Reducing the overall cost of healthcare

•    Key technology advances making personalized medicine possible, including:
o    New tools to decode the human genome
o    Large-scale studies and sample repositories that help link genetic variation to disease
o    Health Information Technology (HIT) that fosters the integration of research and clinical data

•    An exploration of “personal genomics” and direct-to-consumer genetic testing and how the field affects personalized medicine

•    Information about groundbreaking policy, legislation, and government initiatives in place and in development to support personalized medicine, including the Genetic Information Non-Discrimination Act (GINA) passed in 2008 and proposed changes to reimbursement policies

•    Real-world examples of hospitals, regional healthcare systems, and educational institutions promoting clinical adoption of personalized medicine through research, clinical practice, and medical education reform

•    A timeline spotlighting key milestones in the history of personalized medicine

•    A table of selected personalized medicine drugs, treatments, and diagnostics that emphasize the increasing number of personalized medicine products available to help guide treatment

Supported in part by Ernst & Young Global Biotechnology Center, the 20-page PMC report is now available for no charge at or click on the pdf opposite.

About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit

Lynn Blenkhorn
Feinstein Kean Healthcare
(508) 851-0930

Elizabeth Schwinn
Personalized Medicine Coalition
(202) 510-3034